Christopher Moertel

Dr. Christopher Moertel


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 October 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
RGRobert T Galvin
Robert T Galvin
ALAlex T Larsson
Alex T Larsson
MSMeghna Saxena
Meghna Saxena
GFGarrett Fitzpatrick
Garrett Fitzpatrick
DNDavid Nascene
David Nascene
KWKyle Williams
Kyle Williams
Background/Objectives: Histone H3 K27-altered diffuse midline gliomas (DMGs) have poor outcomes and are characterized by global loss of H3K27 trimethylation (H3K27me3). Evidence from other H3K27me3-deficient tumors suggests a potential vulnerability to combined histone deacetylase (HDAC) and MEK inhibition. We examined a clinical experience with this combination and tested its activity in glioma models. Methods: We reviewed the course of an 11-year-old with neurofibromatosis type 1 and a thoracic spinal DMG treated with selumetinib and vorinostat after gross-total resection, without upfront radiotherapy. In post hoc viability assays, we tested HDAC and MEK inhibition in two H3K27M-mutant glioma lines, an isogenic K27-rescued derivative, and two H3-wildtype lines. Combination benefit was measured as the reduction in area under the viability curve relative to vorinostat alone. Results: The patient experienced 22 months of radiotherapy-free, progression-free survival before recurrence, with a postoperative enhancing focus resolving during treatment. Treatment was associated with grade 1 diarrhea and dermatitis. In vitro, combination benefit was greater in the H3K27M-mutant lines than in the H3-wildtype lines (mean difference, 13.2; 95% confidence interval, 8.1–18.3; p < 0.001). Benefit was also greater in DIPG17 than in its K27-rescued derivative (mean difference, 22.4; 95% confidence interval, 10.1–34.7; p = 0.015). Conclusions: This clinical observation and the post hoc validation experiments support prospective study of H3K27me3 loss as a candidate biomarker for combined HDAC and MEK inhibition.

14 February 2026 in medRxiv
Verified
Preprint
Open access
PDF file
MSMeghna Saxena
Meghna Saxena
EMElisabet Ampudia Mesias
Elisabet Ampudia Mesias
SDSumant Dhawan
Sumant Dhawan
SFStephen C Frederico
Stephen C Frederico
XCXiaoqing Cheng
Xiaoqing Cheng
MOMichael Olin
Michael Olin
Background: Immune checkpoint inhibition has transformed cancer therapy; however, many patients fail to respond to single-agent blockade, and combination strategies are often limited by toxicity. Central nervous system tumors exploit multiple immunosuppressive pathways, including the CD200 and PD1/PDL1 axis to evade anti-tumor immunity and support tumor aggressiveness. Methods: We investigated ARL200, a peptide ligand targeting the CD200 activation receptor (CD200AR) using in vitro immune assays, murine syngeneic tumor models, phosphoproteomics, and correlative studies from a first-in-human trial in recurrent glioblastoma. Results: ARL200 exposure activated DAP10/12-dependent signaling and downregulated multiple inhibitory immune checkpoint receptors, including CD200R1, PD1, and CTLA4, and checkpoint ligands, CD200 protein and PD-L1, through suppression of the JAK1-JAK3-SHP-STAT-IKK alpha beta-NF kappa B pathway. Distinct ARL200 variant peptides elicited unique immune responses. In patients with recurrent glioblastoma, ARL200 treatment was associated with immune activation, reduced inhibitory checkpoint expression, and evidence of antigen-specific memory responses without treatment-related toxicity. Conclusions: Targeting CD200AR enables coordinated modulation of multiple immune checkpoints with a single agent, representing a next-generation immunotherapeutic strategy opening a new pathway for treating aggressive malignancies.

10 November 2026 in Current Oncology
Verified
Journal Article
Open access
PDF file
RGRobert T Galvin
Robert T Galvin
ALAlex T Larsson
Alex T Larsson
MSMeghna Saxena
Meghna Saxena
GFGarrett Fitzpatrick
Garrett Fitzpatrick
DNDavid Nascene
David Nascene
KWKyle Williams
Kyle Williams
Background/Objectives: Histone H3 K27-altered diffuse midline gliomas (DMGs) have poor outcomes and are characterized by global loss of H3K27 trimethylation (H3K27me3). Evidence from other H3K27me3-deficient tumors suggests a potential vulnerability to combined histone deacetylase (HDAC) and MEK inhibition. We examined a clinical experience with this combination and tested its activity in glioma models. Methods: We reviewed the course of an 11-year-old with neurofibromatosis type 1 and a thoracic spinal DMG treated with selumetinib and vorinostat after gross-total resection, without upfront radiotherapy. In post hoc viability assays, we tested HDAC and MEK inhibition in two H3K27M-mutant glioma lines, an isogenic K27-rescued derivative, and two H3-wildtype lines. Combination benefit was measured as the reduction in area under the viability curve relative to vorinostat alone. Results: The patient experienced 22 months of radiotherapy-free, progression-free survival before recurrence, with a postoperative enhancing focus resolving during treatment. Treatment was associated with grade 1 diarrhea and dermatitis. In vitro, combination benefit was greater in the H3K27M-mutant lines than in the H3-wildtype lines (mean difference, 13.2; 95% confidence interval, 8.1–18.3; p < 0.001). Benefit was also greater in DIPG17 than in its K27-rescued derivative (mean difference, 22.4; 95% confidence interval, 10.1–34.7; p = 0.015). Conclusions: This clinical observation and the post hoc validation experiments support prospective study of H3K27me3 loss as a candidate biomarker for combined HDAC and MEK inhibition.